Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 12, 2015, Pages 517-527

  Pham, Anh ^a   Ye, Da Wei ^b   Pal, Sumanta ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Adverse event; Immune checkpoint inhibitors; Renal cell carcinoma; Toxicity; Vascular endothelial growth factor

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATEZOLIZUMAB; AXITINIB; BEVACIZUMAB; EVEROLIMUS; IPILIMUMAB; LEVOTHYROXINE; NIVOLUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN A;

ABDOMINAL PAIN; ACUTE RESPIRATORY FAILURE; ADVERSE DRUG REACTION; ALOPECIA; ANEMIA; ANOREXIA; ANTIHYPERTENSIVE THERAPY; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COLITIS; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EMBOLISM; ENDOCRINE DISEASE; FATIGUE; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; NAUSEA; NEUTROPENIA; PAIN; PATIENT MONITORING; PERIPHERAL EDEMA; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHINITIS; SKIN TOXICITY; STOMATITIS; SYSTEMIC THERAPY; THROMBOSIS; THYROID DISEASE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; CARCINOMA, RENAL CELL; COMPLICATION; DISEASE MANAGEMENT; METABOLISM; PATHOLOGY;

CARCINOMA, RENAL CELL; DISEASE MANAGEMENT; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84960434934     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.07.020     Document Type: Review

References (68)

1. Leibovich B.C., Lohse C.M., Crispen P.L., Boorjian S.A., Thompson R.H., Blute M.L., et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010, 183:1309-1315.
2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
3. National Cancer Institute. SEER cancer statistics factsheets: kidney and renal pelvis cancer, ; [accessed 16.04.15]. http://seer.cancer.gov/statfacts/html/kidrp.html.
4. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007, 25:884-896.
5. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
6. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
7. Torino F., Corsello S.M., Longo R., Barnabei A., Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009, 6:219-228.
8. Gore M.E., Szczylik C., Porta C., Bracarda S., Bjarnason G.A., Oudard S., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10:757-763.
9. Atkinson B.J., Kalra S., Wang X., Bathala T., Corn P., Tannir N.M., et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 2014, 191:611-618.
10. Kollmannsberger C., Bjarnason G., Burnett P., Creel P., Davis M., Dawson N., et al. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 2011, 16:543-553.
11. Najjar Y.G., Mittal K., Elson P., Wood L., Garcia J.A., Dreicer R., et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 2014, 50:1084-1089.
12. Sutent® [package insert]. New York (NY): Pfizer Inc.; 2011.
13. Izzedine H., Derosa L., Le Teuff G., Albiges L., Escudier B. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol 2015, 26:1128-1133.
14. Di Lorenzo G., Autorino R., Bruni G., Carteni G., Ricevuto E., Tudini M., et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009, 20:1535-1542.
15. Ewer M.S., Suter T.M., Lenihan D.J., Niculescu L., Breazna A., Demetri G.D., et al. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer 2014, 50:2162-2170.
16. Rini B.I., Tamaskar I., Shaheen P., Salas R., Garcia J., Wood L., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007, 99:81-83.
17. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
18. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
19. Motzer R.J., Hutson T.E., Cella D., Reeves J., Hawkins R., Guo J., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013, 369:722-731.
20. Vortrient® [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2009.
21. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
22. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
23. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Staehler M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
24. Stadler W.M., Figlin R.A., McDermott D.F., Dutcher J.P., Knox J.J., Miller W.H., et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116:1272-1280.
25. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 2011, 16(Suppl. 2):32-44.
26. Nexavar® [package insert]. Wayne, NJ. Bayer HealthCare Pharmaceuticals Onc.; 2009.
27. Rini B.I., Escudier B., Tomczak P., Kaprin A., Szczylik C., Hutson T.E., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
28. Hutson T.E., Lesovoy V., Al-Shukri S., Stus V.P., Lipatov O.N., Bair A.H., et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013, 14:1287-1294.
29. Inlyta® [package insert]. New York (NY): Pfizer; 2012.
30. National Comprehensive Cancer Network (2011) Cancer-related fatigue. ; [Accessed 01.04.15]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
31. Kornblau S., Benson A.B., Catalano R., Champlin R.E., Engelking C., Field M., et al. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage 2000, 19:118-129.
32. Cohen R.B., Oudard S. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs 2012, 30:2066-2079.
33. Rugo H.S., Herbst R.S., Liu G., Park J.W., Kies M.S., Steinfeldt H.M., et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005, 23:5474-5483.
34. Escudier B., Bellmunt J., Negrier S., Bajetta E., Melichar B., Bracarda S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28:2144-2150.
35. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
36. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Ou S.S., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-5428.
37. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Archer L., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143.
38. Avastin® [package insert]. South San Francisco (CA): Genetech Inc.; 2009.
39. Torisel® [package insert]. Philadelphia: Wyeth Pharmaceuticals, Inc.; 2007.
40. Afinitor® [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corp.; 2009.
41. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-348.
42. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
43. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
44. Sonis S., Treister N., Chawla S., Demetri G., Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010, 116:210-215.
45. Kaplan B., Qazi Y., Wellen J.R. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) 2014, 28:126-133.
46. Creel P.A. Management of mTOR inhibitor side effects. Clin J Oncol Nurs 2009, 13(Suppl.):19-23.
47. Campistol J.M., de Fijter J.W., Flechner S.M., Langone A., Morelon E., Stockfleth E. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 2010, 24:149-156.
48. Stokman M.A., Spijkervet F.K., Boezen H.M., Schouten J.P., Roodenburg J.L., de Vries E.G. Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res 2006, 85:690-700.
49. Eilers J., Harris D., Henry K., Johnson L.A. Evidence-based interventions for cancer treatment-related mucositis: putting evidence into practice. Clin J Oncol Nurs 2014, 18(Suppl.):80-96.
50. Porta C., Osanto S., Ravaud A., Climent M.A., Vaishampayan U., White D.A., et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011, 47:1287-1298.
51. Potting C.M., Uitterhoeve R., Op Reimer W.S., Van Achterberg T. The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review. Eur J Cancer Care (Engl) 2006, 15:431-439.
52. Belenguer-Guallar I., Jimenez-Soriano Y., Claramunt-Lozano A. Treatment of recurrent aphthous stomatitis. A literature review. J Clin Exp Dent 2014, 6:e168-e174.
53. Feagans J., Victor D., Moehlen M., Florman S.S., Regenstein F., Balart L.A., et al. Interstitial pneumonitis in the transplant patient: consider sirolimus-associated pulmonary toxicity. J La State Med Soc 2009, 161:166,168-172.
54. Rodriguez-Pascual J., Cheng E., Maroto P., Duran I. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 2010, 21:478-486.
55. Pham P.T., Pham P.C., Danovitch G.M., Ross D.J., Gritsch H.A., Kendrick E.A., et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004, 77:1215-1220.
56. Tykodi S.S. PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther 2014, 7:1349-1359.
57. Lu J., Lee-Gabel L., Nadeau M.C., Ferencz T.M., Soefje S.A. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract 2015, [Epub ahead of print].
58. McDermott D.F., Drake C.G., Sznol M., Choueiri T.K., Powderly J.D., Smith D.C., et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015, 33:2013-2020.
59. Motzer R.J., Rini B.I., McDermott D.F., Redman B.G., Kuzel T.M., Harrison M.R., et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2014, 33:1430-1437.
60. Hammers H.J., Plimack E.R., Infante J.R., et al. Phase I Study of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC) 2014, American Society of Clinical Oncology (ASCO), Chicago, IL.
61. Cho D.C., Sosman J.A., Sznol M., et al. Clinical Activity, Safety, and Biomarkers of MPDL3280A, an Engineered PD-L1 Antibody in Patients With Metastatic Renal Cell Carcinoma (mRCC) 2013, American Society of Clinical Oncology (ASCO), Chicago, IL.
62. Weber J.S. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book 2012, 174-177.
63. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009, 58:823-830.
64. Chmiel K.D., Suan D., Liddle C., Nankivell B., Ibrahim R., Bautista C., et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011, 29:e237-e240.
65. Blansfield J.A., Beck K.E., Tran K., Yang J.C., Hughes M.S., Kammula U.S., et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005, 28:593-598.
66. Dillard T., Yedinak C.G., Alumkal J., Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010, 13:29-38.
67. Carpenter K.J., Murtagh R.D., Lilienfeld H., Weber J., Murtagh F.R. Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol 2009, 30:1751-1753.
68. Opdivo® [package insert]. Princeton (NJ): Bristol-Myers Squibb Company; 2014.